ACTRN12624000233527招募中Unknown
Extension Study to DV2-TDAP-01 to Assess Immunogenicity to Pertussis Antigens Two and a Half to Three Years Following Study Injection or Boostrix
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 26 Years（—）
- 性别
- All
入选标准
- •A participant must meet the following criteria to be eligible for enrollment and participation in
- •1) Willing to participate; informed consent provided for the study
- •2) Male or female, 18 to 22 years of age at time of receipt of Tdap-1018 3000 mcg or Boostrix
- •injection in Dynavax study DV2-TDAP-01
- •3) Able to comprehend and follow all required study procedures
- •4) All participants must have been a part of ACTRN12620001177943 in order to be included in this study.
排除标准
- •A participant with any 1 of the following criteria is not eligible for enrollment in the study:
- •1) Vaccinated against pertussis following receipt of the DV2-TDAP-01 injection and prior to date of study visit in DV2-TDAP-101
- •2) Any other finding that the Investigator considers will make the subject unsuitable for the study
研究者
相似试验
已完成
2 期
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean InfantsHaemophilus Influenzae Type bPoliomyelitisPertussisDiphtheriaTetanusNCT00831311Sanofi Pasteur, a Sanofi Company624
进行中（未招募）
不适用
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers - Focetria TxVaccination for H1N1sw of immunocompromised adults who have undergone solid organ or bone marrow transplantation and of healthy adultsMedDRA version: 12.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-017052-27-DEMedizinische Hochschule Hannover
进行中（未招募）
不适用
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers - Fluad TxEUCTR2010-022871-78-DEMedizinische Hochschule Hannover
进行中（未招募）
1 期
oGlioblastoma is the most common primary brain tumour in humans withthe most severe prognosis. Standard treatments consist primarily ofsurgery in order to debulk thetumoral mass, as well asradiochemotherapy to induce optimal local tumor control. However themedian overall survival (OS)is about 15 months, with 88% of patientsdead within 3 yearsMedDRA version: 18.0Level: HLTClassification code 10045172Term: Tumour vaccine therapiesSystem Organ Class: 100000004865EUCTR2013-005387-25-ITSapienza, University of Rome10
未知
2 期
DNK-651-3JPRN-jRCT2080223664DENKA SEIKEN CO.,LTD.500